Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
PubMed
24581989
DOI
10.1016/j.rbmo.2013.12.009
PII: S1472-6483(14)00010-8
Knihovny.cz E-zdroje
- Klíčová slova
- corifollitropin alfa, infertility, ongoing pregnancy rate, ovarian stimulation, recombinant FSH, short follicular phase,
- MeSH
- časové faktory MeSH
- choriogonadotropin aplikace a dávkování MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- folikulární fáze fyziologie MeSH
- folikuly stimulující hormon lidský aplikace a dávkování MeSH
- folikuly stimulující hormon aplikace a dávkování MeSH
- indukce ovulace metody MeSH
- lidé MeSH
- rekombinantní proteiny aplikace a dávkování MeSH
- retrospektivní studie MeSH
- těhotenství MeSH
- úhrn těhotenství na počet žen v reprodukčním věku MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- choriogonadotropin MeSH
- folikuly stimulující hormon lidský MeSH
- folikuly stimulující hormon MeSH
- follicle stimulating hormone, human, with HCG C-terminal peptide MeSH Prohlížeč
- rekombinantní proteiny MeSH
To evaluate whether a short follicular phase of ovarian stimulation compromises the chance of pregnancy, subjects from a double-blind, randomized trial treated with a single dose of corifollitropin alfa (n=756) or daily recombinant FSH (n=750) were categorized as early responders if three follicles ≥17 mm were reached and human chorionic gonadotrophin (HCG) was administered prior to or on stimulation day 8, and as normal responders if three follicles ≥17 mm were reached and HCG was administered after stimulation day 8. In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). Regardless of the treatment group, the initial ovarian response was higher in early responders, but with two extra days of stimulation, the number and size of follicles on the day of HCG in the normal responders was similar to those of the early responders. The number of oocytes was similar in both response groups following corifollitropin alfa treatment (13.6 versus 14.5) and recombinant FSH treatment (12.8, both groups). The ongoing pregnancy rates were comparable for early and normal responders regardless of the treatment group, supporting successful outcome following a stimulation period of only 1 week.
Center for Reproductive Medicine Hurley Medical Center Flint MI USA
Department of Reproductive Medicine and Gynecology University Medical Center Utrecht The Netherlands
Citace poskytuje Crossref.org